Risultati della ricerca - Restelli U

Financial and feasibility implications of the treatment of hepatitis C virus in Italy: scenarios and perspectives di Croce D, Bonfanti M, Restelli U

Testo

Co-Design as Enabling Factor for Patient-Centred Healthcare: A Bibliometric Literature Review di Silvola S, Restelli U, Bonfanti M, Croce D

Testo

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem... di Restelli U, Croce D, Pacelli V, Ciceri F, Girmenia C

Testo

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy start... di Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D

Testo

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy start... di Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D

Testo

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies... di Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D

Testo

Protocol Implementation for Normothermia in Surgery Settings in Italy: Budget-Impact Analysis di Monzani R, Barbera G, Restelli U, Galeone C, Petrini F

Testo

Health Technology Assessment for Fast-Track Elective Knee and Hip Arthroplasty in a High-Volume Orthopaedic Hospital in Italy di Restelli U, Vitale J, Croce E, Bernareggi S, Guida S, Silvola S, Banfi G, Zagra L

Testo

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatm... di Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D

Testo

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum] di Restelli U, Ceresoli GL, Croce D, Evangelista L, Maffioli LS, Gianoncelli L, Bombardieri E

Testo

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study di Restelli U, Ceresoli GL, Croce D, Evangelista L, Maffioli LS, Gianoncelli L, Bombardieri E

Testo

Cost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile? di Rizzardini G, Restelli U, Bonfanti P, Porazzi E, Ricci E, Foglia E, Carenzi L, Croce D

Testo

Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients w... di Restelli U, Croce D, Bonizzoni E, Marzanatti M, Andreini A, Sorio M, Tecchio C, Barison E, Benedetti F

Testo

Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service di Restelli U, Andreoni M, Antinori A, Bonfanti M, Di Perri G, Galli M, Lazzarin A, Rizzardini G, Croce D

Testo

The Economic Impact of Loss to Follow-Up in Eosinophilic Esophagitis: A Model-Based Analysis from the Perspective of Italian National Health Service di Bonfanti M, Fardella M, Morani M, Oliva S, Savarino EV, Giodice R, Saab JP, Castagnaro E, Tassone A, Restelli U

Testo

Role of Inhaled Methoxyflurane in the Management of Acute Trauma Pain di Fabbri A, Ruggiano G, Garcia Collado S, Ricard-Hibon A, Restelli U, Sbrana G, Marinangeli F, Farina A, Coffey F

Testo

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum] di Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A

Testo

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey di Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A

Testo

Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district di Polilli E, Cento V, Restelli U, Ceccherini-Silberstein F, Aragri M, Di Maio VC, Sciacca A, Santoleri F, Fazii P, Costantini A, Perno CF, Parruti G

Testo